Stocks Health care MBRX
NASDAQ · Health careMoleculin Biotech, Inc. (MBRX)
Moleculin Biotech, Inc. brought in $0 of revenue over the twelve months to June 30, 2026. It posted a net loss of $30.3M. In fiscal 2025 capital spending exceeded operating cash flow by $22.7M. At June 30, 2026 it held $7.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
What Moleculin Biotech, Inc. does
Moleculin Biotech, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MBRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$33.6M | -$28.42 | -$22.7M |
| 2024 | $0 | -$26M | -$189.14 | -$23.9M |
| 2023 | $0 | -$29.8M | -$451.00 | -$23.7M |
| 2022 | $0 | -$29M | -$455.49 | -$27.7M |
| 2021 | $0 | -$15.9M | -$17.66 | -$19M |
| 2020 | $0 | -$17.4M | -$52.67 | -$18.1M |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Moleculin Biotech, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 25, 2026
- September 23, 2026
- September 18, 2026
- September 14, 2026
- August 31, 2026
- August 25, 2026Activist stake (5% or more) SCHEDULE 13D
- August 25, 2026Activist stake (5% or more) SCHEDULE 13D
- August 24, 2026Additional proxy material DEFA14A
- August 24, 2026Proxy statement DEF 14A
- August 21, 2026
Insider trades
What the people running Moleculin Biotech, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought shares on the open market in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 3, 2026 | Picker Donald HChief Science Officer | Bought | 173,333 | - |
| August 3, 2026 | Klemp Walter VCEO and President, Director | Bought | 533,333 | - |
| August 3, 2026 | Foster Jonathan P.Chief Financial Officer | Bought | 293,333 | - |
| June 22, 2026 | Foster Jonathan P.Chief Financial Officer | Exercised options | 174 | - |
| June 22, 2026 | Foster Jonathan P.Chief Financial Officer | Shares withheld for tax | 41 | $127.9 |
| June 22, 2026 | Klemp Walter VCEO and President, Director | Exercised options | 360 | - |
| June 22, 2026 | Klemp Walter VCEO and President, Director | Shares withheld for tax | 88 | $274.6 |
| June 22, 2026 | Picker Donald HChief Science Officer | Exercised options | 71 | - |
| June 22, 2026 | Picker Donald HChief Science Officer | Shares withheld for tax | 21 | $65.5 |
| June 20, 2026 | Foster Jonathan P.Chief Financial Officer | Exercised options | 109 | - |
| June 20, 2026 | Foster Jonathan P.Chief Financial Officer | Shares withheld for tax | 31 | $89.3 |
| June 20, 2026 | Klemp Walter VCEO and President, Director | Exercised options | 150 | - |
| June 20, 2026 | Klemp Walter VCEO and President, Director | Shares withheld for tax | 37 | $106.6 |
| June 20, 2026 | Picker Donald HChief Science Officer | Exercised options | 44 | - |
| June 20, 2026 | Picker Donald HChief Science Officer | Shares withheld for tax | 13 | $37.4 |
Who owns MBRX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| CVI Investments, Inc.13G, passive with 1 related filers | 9.9% | August 10, 2026 |
| Klemp Walter V13D, may seek influence with 1 related filers | 9.9% | August 25, 2026 |
| Foster Jonathan P.13D, may seek influence | 6.3% | August 25, 2026 |
Largest institutional holders
Insiders
3 insiders reported holding 1,044,099 shares in total, about $628.1K at the last price.
| Holder | Shares |
|---|---|
| Klemp Walter VCEO and President, Director | 564,340 |
| Foster Jonathan P.Chief Financial Officer | 305,673 |
| Picker Donald HChief Science Officer | 174,086 |
Questions about MBRX
What does Moleculin Biotech, Inc. do?
Moleculin Biotech, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MBRX.
Is Moleculin Biotech, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $30.3M.
How much revenue does Moleculin Biotech, Inc. make?
Over the twelve months to June 30, 2026 Moleculin Biotech, Inc. reported revenue of $0.
When did Moleculin Biotech, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 25, 2026.
Similar companies
Compare MBRX with
Follow MBRX
Get an email when Moleculin Biotech, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow MBRX: get an email when it filesWhere the numbers come from
Financial figures are the values Moleculin Biotech, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.